Dataset Information

Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

ABSTRACT: BACKGROUND:Blunted facial affect is a common negative symptom of schizophrenia. Additionally, assessing the trustworthiness of faces is a social cognitive ability that is impaired in schizophrenia. Currently available pharmacological agents are ineffective at improving either of these symptoms, despite their clinical significance. The hypothalamic neuropeptide oxytocin has multiple prosocial effects when administered intranasally to healthy individuals and shows promise in decreasing negative symptoms and enhancing social cognition in schizophrenia. Although two small studies have investigated oxytocin's effects on ratings of facial trustworthiness in schizophrenia, its effects on facial expressivity have not been investigated in any population. METHOD:We investigated the effects of oxytocin on facial emotional expressivity while participants performed a facial trustworthiness rating task in 33 individuals with schizophrenia and 35 age-matched healthy controls using a double-blind, placebo-controlled, cross-over design. Participants rated the trustworthiness of presented faces interspersed with emotionally evocative photographs while being video-recorded. Participants' facial expressivity in these videos was quantified by blind raters using a well-validated manualized approach (i.e. the Facial Expression Coding System; FACES). RESULTS:While oxytocin administration did not affect ratings of facial trustworthiness, it significantly increased facial expressivity in individuals with schizophrenia (Z = -2.33, p = 0.02) and at trend level in healthy controls (Z = -1.87, p = 0.06). CONCLUSIONS:These results demonstrate that oxytocin administration can increase facial expressivity in response to emotional stimuli and suggest that oxytocin may have the potential to serve as a treatment for blunted facial affect in schizophrenia.

SUBMITTER: Woolley JD

PROVIDER: S-EPMC6939989 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

Woolley J D JD Chuang B B Fussell C C Scherer S S Biagianti B B Fulford D D Mathalon D H DH Vinogradov S S

Psychological medicine 20170116 7

<h4>Background</h4>Blunted facial affect is a common negative symptom of schizophrenia. Additionally, assessing the trustworthiness of faces is a social cognitive ability that is impaired in schizophrenia. Currently available pharmacological agents are ineffective at improving either of these symptoms, despite their clinical significance. The hypothalamic neuropeptide oxytocin has multiple prosocial effects when administered intranasally to healthy individuals and shows promise in decreasing neg ...[more]

PMID: 28091349

Similar Datasets

Project description:Individuals with schizophrenia show deficits both in facial emotion recognition and context processing (Kohler, C.G., Walker, J.B., Martin, E.A., Healey, K.M., Moberg, P.J., 2010. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr. Bull. 36, 1009-1019). Recent evidence suggests context information can affect facial emotion recognition (Aviezer, H., Bentin, S., Hassin, R.R., Meschino, W.S., Kennedy, J., Grewal, S., Esmail, S., Cohen, S., Moscovitch, M., 2009. Not on the face alone: perception of contextualized face expressions in Huntington's disease. Brain 132, 1633-1644). Thus, individuals with schizophrenia may have deficits in facial emotion processing, at least in part, due to impairments in processing context information (Green, M.J., Waldron, J.H., Coltheart, M., 2007. Emotional context processing is impaired in schizophrenia. Cogn. Neuropsychiatry 12, 259-280.). We used a novel experimental task, the Emotion Context Processing Task (ECPT) to examine the influences of emotional context (IAPS pictures) on the processing of subtle surprised faces in schizophrenia. One of the task conditions included a manipulation designed to determine whether enhancing attention to the context (by requiring a categorization judgment on the context pictures) would facilitate the influence of context on facial emotion processing in schizophrenia. In addition, we tested whether deficits on a non-social context processing would predict deficits in the influence of context on facial emotion processing in schizophrenia. We administered the Dot Probe Expectancy Task (a non-social context processing task) and the ECPT to individuals with schizophrenia (n=35) and healthy controls (n=32). Individuals with schizophrenia showed an intact influence of context information on facial emotion recognition. The manipulation designed to enhance attention to emotional context reduced the effect of context for both groups. In schizophrenia, better processing of non-social context was associated with a stronger influence of context on valence ratings of facial expressions in the negative context condition. These results suggest in schizophrenia, similar mechanisms may influence the processing of context for both social and non-social information.

Project description:Advances in the treatment of bulimia nervosa and binge-eating disorder (BN/BED) have been marred by our limited understanding of the underpinning neurobiology. Here we measured regional cerebral blood flow (rCBF) to map resting perfusion abnormalities in women with BN/BED compared with healthy controls and investigate whether intranasal oxytocin (OT), proposed as a potential treatment, can restore perfusion in disorder-related brain circuits. Twenty-four women with BN/BED and 23 healthy women participated in a randomized, double-blind, crossover, placebo-controlled study. We used arterial spin labelling MRI to measure rCBF and the effects of an acute dose of intranasal OT (40 IU) or placebo over 18-26 min post dosing, as we have previously shown robust OT-induced changes in resting rCBF in men in a similar time-window (15-36 min post dosing). We tested for effects of treatment, diagnosis and their interaction on extracted rCBF values in anatomical regions-of-interest previously implicated in BN/BED by other neuroimaging modalities, and conducted exploratory whole-brain analyses to investigate previously unidentified brain regions. We demonstrated that women with BN/BED presented increased resting rCBF in the medial prefrontal and orbitofrontal cortices, anterior cingulate gyrus, posterior insula and middle/inferior temporal gyri bilaterally. Hyperperfusion in these areas specifically correlated with eating symptoms severity in patients. Our data did not support a normalizing effect of intranasal OT on perfusion abnormalities in these patients, at least for the specific dose (40 IU) and post-dosing interval (18-26 min) examined. Our findings enhance our understanding of resting brain abnormalities in BN/BED and identify resting rCBF as a non-invasive potential biomarker for disease-related changes and treatment monitoring. They also highlight the need for a comprehensive investigation of intranasal OT pharmacodynamics in women before we can fully ascertain its therapeutic value in disorders affecting predominantly this gender, such as BN/BED.

Dataset Information

Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

Publications

Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure